Scarica l'app Stockscreener
9.60
7.43%
-0.77
Dopo l'orario di chiusura:
9.50
-0.10
-1.04%
Precedente Chiudi:
$10.37
Aprire:
$10.54
Volume 24 ore:
2.00M
Relative Volume:
2.19
Capitalizzazione di mercato:
$658.89M
Reddito:
-
Utile/perdita netta:
$-96.66M
Rapporto P/E:
-4.4651
EPS:
-2.15
Flusso di cassa netto:
$-83.73M
1 W Prestazione:
-10.11%
1M Prestazione:
+21.67%
6M Prestazione:
+125.35%
1 anno Prestazione:
-21.95%
Intervallo 1D:
$9.58
$10.76
Intervallo di 1 settimana:
$9.58
$11.34
Portata 52W:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Confronta OLMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
9.60 | 737.13M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential - Insider Monkey
Leading vs lagging indicators on Olema Pharmaceuticals Inc. performanceEarnings Summary Report & Breakout Confirmation Alerts - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutSell Signal & High Return Stock Watch Alerts - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsPortfolio Risk Report & Risk Adjusted Buy/Sell Alerts - newser.com
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.Portfolio Value Summary & Expert Approved Momentum Ideas - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Volume & Smart Investment Allocation Insights - newser.com
12 Best Hot Stocks to Invest In - Insider Monkey
Published on: 2025-10-13 10:23:49 - newser.com
Using flow based indicators on Olema Pharmaceuticals Inc.Earnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Institutional scanner results for Olema Pharmaceuticals Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Why Olema Pharmaceuticals Inc. stock attracts global investorsWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7%What's Next? - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Can momentum traders help lift Olema Pharmaceuticals Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Guggenheim Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Does Olema Pharmaceuticals Inc. fit your quant trading modelEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Is now a turning point for Olema Pharmaceuticals Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trendsMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - Defense World
Guggenheim Initiates Coverage on OLMA with a 'Buy' Rating and $2 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim initiates coverage on Olema Pharmaceuticals stock with Buy rating - Investing.com
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - Defense World
What analysts say about Olema Pharmaceuticals Inc stockAnalyst Upgrades & Low Cost Portfolio Ideas - earlytimes.in
How moving averages guide Olema Pharmaceuticals Inc. tradingStop Loss & Stock Portfolio Risk Control - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time seriesJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Metastatic HR+/HER2− Breast Cancer Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Menafn.com
Metastatic HR+/HER2− Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Barchart.com
Metastatic HR+/HER2 Breast Cancer Market Positioned - openPR.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart based exit strategy for Olema Pharmaceuticals Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
77,000-share award: Olema Pharmaceuticals grants stock options at $11.04 as inducement - Stock Titan
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3%Time to Sell? - MarketBeat
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Olema Pharmaceuticals Inc Azioni (OLMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.04 |
10,000 |
80,400 |
754,140 |
| Harmon Cyrus | Director |
Sep 18 '25 |
Sale |
8.32 |
3,086 |
25,676 |
117,028 |
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.08 |
1,914 |
15,465 |
120,114 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):